NVCR
NovoCure LtdPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 NovoCure reported 8% year-over-year revenue growth for Q4 and full y…
- Mar 3 to Mar 5 ▼ 3 days of insider sells: $1.6M by 7 insiders, avg $13.26
- Jun 2 to Jun 4 ▼ 2 days of insider sells: $939.7K by 8 insiders, avg $17.12
- Jun 18 ▼ NovoCure announced that its Phase 3 TRIDENT trial failed to meet the…
- Jun 30 ▲ NovoCure announced that its Optune Pax device received CE Mark for t…
- Jul 23 ▲ Novocure reported Q2 2026 net revenues of $183.6M (+16% YoY), beatin…
- Oct 1 ▲ NovoCure announced that Japan's MHLW approved Optune Pax for unresec…
- Oct 29 ▲ Earnings: NVCR Q3 2026 Earnings: EPS $-0.09 (+63.9% vs est)
- Oct 29 ▲ Novocure reported Q3 2026 net revenues of $193.4M (+16% YoY), above…
- Nov 2 to Nov 9 ▼ 2 days of insider sells: $142.8K by 3 insiders, avg $12.88
- Nov 9 ▼ NovoCure received a Not Approvable Letter from the FDA for its PMA a…
Signal stack
Where each data set points today.
- InsidersBEARISH
14 insiders sold $2.7M.
- InstitutionsBULLISH
Q3 2026: 32 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
9 of 13 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.251 → −$0.214 over 90 days. 5 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +0.7% to 12.91M shares. 6.0 days to cover, ≈11.1% of shares.
- TrendDOWNTREND
23% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Quantinno Capital Management LP | ADD | $67.4M |
| MACKENZIE FINANCIAL CORP | DOUBLED | $18.8M |
| JPMORGAN CHASE & CO | TRIM | $15.6M |
| Qube Research & Technologies Ltd | ADD | $14.7M |
| Empowered Funds, LLC | TRIM | $9.9M |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | TRIM | $6.4M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $5.7M |
| FIRST TRUST ADVISORS LP | DOUBLED | $5.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is below the lowest target. Median implies +77%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | Ladenburg Thalmann MAINTAIN | Buy |
| Nov 10, 2026 | Wedbush MAINTAIN | Neutral |
| Oct 30, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
| Oct 30, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Jul 24, 2026 | Wedbush MAINTAIN | Neutral |
| Jul 23, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Brackmann Christoph Chief Financial Officer Nov 9, 2026 | SELL | $94.4K |
Paravasthu Mukund Chief Operating Officer Nov 9, 2026 | SELL | $39.6K |
Puri Michal Nath Chief Human Resources Officer Nov 2, 2026 | SELL | $8.7K |
Leonard Frank X Chief Executive Officer Jun 30, 2026 | AWARD | $21.2K |
Danziger Asaf Director Jun 30, 2026 | AWARD | $3.0K |
Ben Arye Barak General Counsel Jun 30, 2026 | AWARD | $14.5K |
Puri Michal Nath Chief Human Resources Officer Jun 30, 2026 | AWARD | $21.2K |
Leonard Frank X Chief Executive Officer Jun 4, 2026 | SELL | $614.6K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.21 | -$0.25–-$0.19 | +11.3% | $189.7M |
| Next Q | -$0.20 | -$0.25–-$0.13 | +9.3% | $189.4M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 4 bullish · 3 bearish · 1 mixed · 12 neutral- NEUTRAL CLUSTERNov 12, 2026
Two NovoCure insiders, including the CFO and CHRO, sold shares in open-market transactions…
The dollar value of insider sales is negligible relative to market cap, indicating routine portfolio diversification rather than a negative signal. Monitor next earnings release for any operational…
- NEUTRAL SC 13G/ANov 9, 2026
Soleus Capital Master Fund filed an amended Schedule 13G disclosing a 8.1% passive stake in…
Soleus Capital remains a significant passive holder at 8.1%. Monitor for any future conversion to a 13D filing, which would signal activist intent, especially given the recent positive Q3 earnings…
- NEUTRAL 144Nov 9, 2026
Christoph Brackmann, an officer of NovoCure, filed a Form 144 notice of intent to sell 7,343…
The sale is small relative to market cap and likely a routine diversification move by an officer. Monitor for any subsequent Form 4 filings to confirm execution and for any pattern of larger insider…
- BEARISH 8-KNov 9, 2026
NovoCure received a Not Approvable Letter from the FDA for its PMA application for Optune Mya to…
Monitor for updates from the FDA meeting and any subsequent resubmission plans. The rejection removes a key pipeline catalyst for NVCR, and the stock may re-rate lower until a clear path to approval…
All NVCR filing & press-release reports (20)
- CLUSTER reportNov 12, 2026
- SC 13G/A reportNov 9, 2026
- 144 reportNov 9, 2026
- 8-K reportNov 9, 2026
- 8-K reportOct 29, 2026
- 8-K reportOct 1, 2026
- 8-K reportSep 9, 2026
- 8-K reportSep 1, 2026
- 8-K reportJul 23, 2026
- 8-K reportJun 30, 2026
- 8-K reportJun 18, 2026
- 8-K reportJun 5, 2026
- CLUSTER reportJun 3, 2026
- CLUSTER reportJun 3, 2026
- DEFA14A reportApr 20, 2026
- CLUSTER reportFeb 27, 2026
- CLUSTER reportFeb 27, 2026
- CLUSTER reportFeb 27, 2026
- 8-K reportFeb 26, 2026
- 8-K reportFeb 24, 2026